PEG: Net loss improved to DKK -2.7m, with strengthened IP and ongoing licensing discussions
閱讀少於1分鐘
Net loss narrowed to DKK -2.7m in H1 2026, driven by cost reductions and a DKK 5.6m Portinho receivable revaluation. Clinical and IP progress continued, with new patents and ongoing licensing discussions. Guidance reflects uncertainty around licensing and clinical study timing.
Original document: Pharma Equity Group A/S Class A [PEG] Slides Release — Aug. 14 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr